NASDAQ$HROW
Harrow Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Harrow experienced growth and launched key products, setting the stage for future expansion.
Harrow announced its fourth quarter and year-end 2023 financial results, highlighting the company's transformation and growth in the ophthalmic pharmaceuticals market. The company launched products and began generating cash from IHEEZO, VEVYE, and TRIESENCE.
- Harrow transformed from a company focused on compounded business to a leader in ophthalmic pharmaceuticals.
- The company launched products and began generating cash from its Big Three products: IHEEZO, VEVYE, and TRIESENCE.
- Harrow attracted experienced talent, setting the stage for growth in 2024.
- The company expects significant growth from IHEEZO and continued success with VEVYE.
Headline financials
Revenue & EPS history
Harrow · Revenue · Quarterly
$36.4M
Forward guidance
Harrow anticipates continued growth and success, driven by its product portfolio and strategic initiatives.
Tailwinds
- Significant growth expected from IHEEZO.
- Continued success with VEVYE launch.
- Potential return of TRIESENCE to inventory this year.
- Company has the products, resources, and people to take advantage of opportunities.
- 2024 is shaping up to be another exciting year of growth.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
+1.6%
Avg return
Earnings day
+3.0%
Avg return
5 days after
+8.7%
Avg return
30 days after
52%
25 / 48 earnings
Positive
+49.3%
Q2 2024
Best reaction
-36.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.4% | -18.5% | — | |
| Q4 2025 | +2.3% | -32.2% | -34.1% | |
| Q3 2025 | +13.6% | +19.5% | +49.7% | |
| Q1 2025 | +3.4% | +6.5% | +25.4% | |
| Q4 2024 | -6.0% | +21.8% | +2.9% | |
| Q3 2024 | -14.1% | -23.9% | -28.9% | |
| Q2 2024 | +49.3% | +56.3% | +67.2% | |
| Q1 2024 | +40.0% | +44.5% | +57.3% | |
| Q4 2023 | +0.3% | +9.6% | +3.4% | |
| Q3 2023 | -36.0% | -30.2% | -21.7% | |
| Q2 2023 | -17.4% | -14.7% | -26.8% | |
| Q1 2023 | -20.5% | -24.1% | -26.9% | |
| Q4 2022 | +6.7% | +22.9% | +42.6% | |
| Q3 2022 | -4.2% | -9.4% | +10.5% | |
| Q2 2022 | +12.2% | +24.6% | +32.6% | |
| Q1 2022 | +3.3% | -5.3% | +15.3% | |
| Q4 2021 | +3.0% | -1.4% | -1.7% | |
| Q3 2021 | -4.9% | -3.3% | -21.1% | |
| Q2 2021 | -0.3% | -0.8% | +13.0% | |
| Q1 2021 | +15.8% | +14.5% | +14.0% | |
| Q4 2020 | +3.5% | +3.4% | -12.3% | |
| Q3 2020 | +25.8% | +30.0% | +19.9% | |
| Q2 2020 | +4.8% | +10.4% | +15.0% | |
| Q1 2020 | -5.8% | -9.7% | +36.5% | |
| Q4 2019 | -7.5% | -16.0% | -3.8% | |
| Q3 2019 | +18.6% | +16.1% | +33.8% | |
| Q2 2019 | -23.6% | -21.7% | -8.0% | |
| Q1 2019 | +10.1% | +16.5% | +26.6% | |
| Q4 2018 | -7.5% | -20.3% | -30.1% | |
| Q3 2018 | +7.2% | +23.0% | +38.4% | |
| Q2 2018 | +13.4% | +29.3% | +26.4% | |
| Q1 2018 | +9.3% | +5.3% | +6.2% | |
| Q4 2017 | -3.4% | -5.3% | -3.9% | |
| Q3 2017 | +5.7% | +19.1% | +7.6% | |
| Q2 2017 | -7.9% | -9.7% | -28.2% | |
| Q1 2017 | -4.8% | -12.6% | -22.5% | |
| Q4 2016 | +2.9% | +17.0% | +79.7% | |
| Q3 2016 | -9.8% | -13.2% | -28.9% | |
| Q2 2016 | -3.1% | -2.6% | +6.5% | |
| Q1 2016 | +1.9% | — | — | |
| Q4 2015 | -2.2% | — | — | |
| Q3 2015 | -6.2% | — | — | |
| Q2 2015 | -1.3% | — | — | |
| Q1 2015 | +1.3% | — | — | |
| Q4 2014 | +3.5% | — | — | |
| Q3 2014 | -2.7% | — | — | |
| Q2 2014 | +7.8% | — | — | |
| Q2 2010 | -1.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro